Autolus Therapeutics plc (AUTL) stock
AUTLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 5/3020% below fair value
$1.09−0.05 (-4.39%)
Close on Nov 17, 2026Market cap $290.12MP/E –Yield –
Autolus Therapeutics profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Autolus Therapeutics's profit margin for the twelve months ending Jun 30, 2026 was -238.7%. For fiscal 2025 it was -381.4%, against -2180.5% the year before. The highest annual figure on record is -381.4% in fiscal 2025.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -381.4% | +1799.1 |
| FY2024 | Dec 31, 2024 | -2180.5% | +10091.8 |
| FY2023 | Dec 31, 2023 | -12272.3% | −9091.7 |
| FY2018 | Sep 30, 2018 | -3180.6% | −2015.4 |
| FY2017 | Sep 30, 2017 | -1165.2% | −129.7 |
| FY2016 | Sep 30, 2016 | -1035.5% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026CQ2 2026 | Jun 30, 2026 | -85.6% | +143.4 |
| Q1 FY2026CQ1 2026 | Mar 31, 2026 | -273.1% | +508.0 |
| Q4 FY2025CQ4 2025 | Dec 31, 2025 | -371.9% | +94821.2 |
| Q3 FY2025CQ3 2025 | Sep 30, 2025 | -373.3% | +148.8 |
| Q2 FY2025CQ2 2025 | Jun 30, 2025 | -229.0% | +12137.5 |
| Q1 FY2025CQ1 2025 | Mar 31, 2025 | -781.1% | +10155.7 |
| Q4 FY2024CQ4 2024 | Dec 31, 2024 | -95193.1% | −86354.9 |
| Q1 FY2024CQ1 2024 | Mar 31, 2024 | -522.1% | +3666.8 |
| Q1 FY2021CQ1 2021 | Mar 31, 2021 | -12366.5% | −10639.7 |
| Q2 FY2020CQ2 2020 | Jun 30, 2020 | -10936.9% | −7679.7 |
| Q1 FY2020CQ1 2020 | Mar 31, 2020 | -8838.2% | – |
| Q4 FY2018CQ3 2018 | Sep 30, 2018 | -4188.9% | – |
| Q3 FY2018CQ2 2018 | Jun 30, 2018 | -1726.9% | – |
| Q1 FY2018CQ4 2017 | Dec 31, 2017 | -3257.1% | – |
See a number that looks wrong?